Abnormal angiogenesis is associated with myriad human diseases, including proliferative diabetic retinopathy (PDR). Signaling transduction through phosphoinositide 3-kinases (PI3Ks) plays a critical role in angiogenesis. Herein, we showed that p110δ, the catalytic subunit of PI3Kδ, was highly expressed in pathological retinal vascular endothelial cells (ECs) in a mouse model of oxygen-induced retinopathy (OIR) and in fibrovascular membranes from patients with PDR. To explore novel intervention with PI3Kδ expression, we developed a recombinant dual adeno-associated viral (rAAV) system for delivering CRISPR/Cas9 in which Streptococcus pyogenes (Sp) Cas9 expression was driven by an endothelial specific promoter of the intercellular adhesion molecule 2 (pICAM2) to edit genomic Pik3cd, the gene encoding p110δ. We then demonstrated that infection of cultured mouse vascular ECs with the dual rAAV1s of rAAV1-pICAM2-SpCas9 and rAAV1-SpGuide targeting genomic Pik3cd resulted in 80% DNA insertion/deletion in the locus of genomic Pik3cd and 70% depletion of p110δ expression. Furthermore, we showed that in the mouse model of OIR editing retinal Pik3cd with the dual rAAV1s resulted in not only a significant decrease in p110δ expression, and Akt activation, but also a dramatic reduction in pathological retinal angiogenesis. These findings reveal that Pik3cd editing is a novel approach to treating abnormal retinal angiogenesis.
FolkmanJ. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995; 1:27–31.
3.
CabreraAP, MonickarajF, RangasamyS, et al.Do genomic factors play a role in diabetic retinopathy?. J Clin Med, 2020; 9:216.
4.
HansenED, HartnettME. A review of treatment for retinopathy of prematurity. Expert Rev Ophthalmol, 2019; 14:73–87.
5.
MillerJW. Developing therapies for age-related macular degeneration: the art and science of problem-solving: the 2018 Charles L. Schepens, MD, Lecture. Ophthalmol Retina, 2019; 3:900–909.
6.
MimuraR, MoriK, ToriiH, et al.Ultra-widefield retinal imaging for analyzing the association between types of pathological myopia and posterior staphyloma. J Clin Med, 2019; 8:1505.
7.
ZhuDD, LiuX. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in branch retinal vein occlusion. J Ophthalmol, 2019; 2019:6043612.
8.
SengerDR, GalliSJ, DvorakAM, et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983; 219:983–985.
9.
FerraraN, HenzelWJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989; 161:851–858.
10.
Lopes-CoelhoF, MartinsF, PereiraSA, et al.Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci, 2021; 22:3765.
11.
FerraraN, HillanKJ, GerberHP, et al.Discovery and development of bevasizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 2004; 3:391–400.
12.
BhisitkulRB, DesaiSJ, BoyerDS, et al.Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology, 2016; 123:1269–1277.
13.
GrunwaldJE, PistilliM, DanielE, et al.Comparison of age-related macular degeneration treatments trials research G: incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology, 2017; 124:97–104.
14.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
15.
RuanGX, BarryE, YuD, et al.CRISPR/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10. Mol Ther, 2017; 25:331–341.
16.
MaederML, StefanidakisM, WilsonCJ, et al.Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med, 2019; 25:229–233.
17.
GarafaloAV, CideciyanAV, HeonE, et al.Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives. Prog Retin Eye Res, 2020; 77:100827.
18.
WangD, ZhangF, GaoG. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell, 2020; 181:136–150.
19.
ConstableIJ, PierceCM, LaiCM, et al.Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine, 2016; 14:168–175.
20.
BulchaJT, WangY, MaH, et al.Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther, 2021; 6:53.
21.
KnottGJ, DoudnaJ. CRISPR-Cas guides the future of genetic engineering. Science, 2018; 361:866–869.
22.
KimE, KooT, ParkSW, et al.In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun, 2017; 8:14500.
23.
HuangX, ZhouG, WuW, et al.Genome editing abrogates angiogenesis in vivo. Nat Commun, 2017; 8:112.
24.
ConnorKM, KrahNM, DennisonRJ, et al.Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc, 2009; 4:1565–1573.
25.
LambertV, LecomteJ, HansenS, et al.Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat Protoc, 2013; 8:2197–2211.
26.
ShenJ, XiaoR, BairJ, et al.Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study. Cell Death Dis, 2018; 9:1018.
27.
DimmelerS, ZeiherAM. Akt takes center stage in angiogenesis signaling. Circ Res, 2000; 86:4–5.
28.
TokerA, DibbleCC. PI 3-kinase signaling: AK ting up inside the cell. Mol Cell, 2018; 71:875–876.
29.
BilangesB, PosorY, VanhaesebroeckB. PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol, 2019; 20:515–534.
30.
WuW, ZhouG, HanH, et al.PI3Kdelta as a novel therapeutic target in pathological angiogenesis. Diabetes, 2020; 69:736–748.
31.
CuiJ, LeiH, SamadA, et al.PDGF receptors are activated in human epiretinal membranes. Exp Eye Res, 2009; 88:438–444.
32.
HuangX, ZhouG, WuW, et al.Editing VEGFR2 blocks VEGF-induced activation of Akt and tube formation. Invest Ophthalmol Vis Sci, 2017; 58:1228–1236.
33.
SwiechL, HeidenreichM, BanerjeeA, et al.In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol, 2015; 33:102–106.
34.
SanjanaNE, ShalemO, ZhangF. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods, 2014; 11:783–784.
35.
OkkenhaugK, BilancioA, FarjotG, et al.Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science, 2002; 297:1031–1034.
36.
TabebordbarM, ZhuK, ChengJK, et al.In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science, 2016; 351:407–411.
37.
HanH, ChenN, HuangX, et al.Phosphoinositide 3-kinase delta inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells. J Biol Chem, 2019; 294:15408–15417.
38.
WangZ, GersteinM, SnyderM. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet, 2009; 10:57–63.
39.
LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014; 15:550.
40.
LeiH, RomeoG, KazlauskasA. Heat shock protein 90alpha-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ Res, 2004; 94:902–909.
41.
LeiH, RheaumeMA, CuiJ, et al.A novel function of p53: a gatekeeper of retinal detachment. Am J Pathol, 2012; 181:866–874.
42.
BeckerK, KleinH, SimonE, et al.In-depth transcriptomic analysis of human retina reveals molecular mechanisms underlying diabetic retinopathy. Sci Rep, 2021; 11:10494.
43.
VanhaesebroeckB, WelhamMJ, KotaniK, et al.P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A, 1997; 94:4330–4335.
44.
WhiteheadMA, BombardieriM, PitzalisC, et al.Isoform-selective induction of human p110delta PI3K expression by TNFalpha: identification of a new and inducible PIK3CD promoter. Biochem J, 2012; 443:857–867.
45.
GeraldesP, Hiraoka-YamamotoJ, MatsumotoM, et al.Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med, 2009; 15:1298–1306.
46.
CroninT, VandenbergheLH, HantzP, et al.Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med, 2014; 6:1175–1190.
47.
KinoseY, SawadaK, MakinoH, et al.IKKbeta regulates VEGF expression and is a potential therapeutic target for ovarian cancer as an antiangiogenic treatment. Mol Cancer Ther, 2015; 14:909–919.
48.
AnzaloneAV, RandolphPB, DavisJR, et al.Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 2019; 576:149–157.
49.
GjaltemaRAF, SchulzEG. CRISPR/dCas9 switch systems for temporal transcriptional control. Methods Mol Biol, 2018; 1767:167–185.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
